Dermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland.
JAMA Dermatol. 2023 May 1;159(5):536-540. doi: 10.1001/jamadermatol.2023.0061.
Racial and ethnic differences in skin cancer outcomes are understudied. Delineating these differences in Merkel cell carcinoma (MCC) is needed to better understand this rare disease.
To determine how MCC presentation and outcomes differ across racial and ethnic groups.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included patients diagnosed with MCC and followed up from 2000 through 2018 in the 18 population-based cancer registries of the National Cancer Institute's Surveillance, Epidemiology, and End Results Program. Patients without follow-up data were excluded. Data analysis occurred from March 12 to November 30, 2022.
A Cox proportional hazards regression was conducted to determine associations between demographic variables (race and ethnicity, age, sex, and income) and clinical variables (stage at diagnosis, primary site, and diagnosis year) with MCC-specific survival.
Of the 9557 patients with MCC identified (6758 [70.7%] aged ≥70 years; 6008 [62.9%] male), 222 (2.3%) were Asian American or Pacific Islander, 146 (1.5%) Black, 541 (5.7%) Hispanic, and 8590 (89.9%) White. Hispanic patients had improved MCC-specific survival compared with White patients (hazard ratio, 0.82; 95% CI, 0.67-0.99; P = .04). Black patients had the lowest MCC-specific survival, but it was not statistically different from White patients (hazard ratio, 1.19; 95% CI, 0.86-1.60; P = .28). Hispanic and Black patients were less likely to present with a primary site of the head and neck than White patients (183 of 541 [33.8%] Hispanic patients and 45 of 146 [30.8%] Black patients vs 3736 of 8590 [43.5%] White patients; P < .001 and P = .002, respectively). Black patients presented more often than White patients with advanced disease at diagnosis (59 of 146 [40.4%] vs 2510 of 8590 [29.2%]; P = .004).
In this cohort study, there were differences between racial and ethnic groups in observed MCC outcomes and disease characteristics. Further investigations are warranted into the findings that, compared with White patients, Hispanic patients with MCC had improved outcomes and Black patients did not have worse outcomes despite presenting with more advanced disease.
皮肤癌结局的种族和民族差异研究不足。为了更好地了解这种罕见疾病,有必要阐明 Merkel 细胞癌 (MCC) 中的这些差异。
确定 MCC 在不同种族和族裔群体中的表现和结局有何不同。
设计、地点和参与者:这项回顾性队列研究纳入了 2000 年至 2018 年间在美国国立癌症研究所监测、流行病学和最终结果计划的 18 个基于人群的癌症登记处中诊断为 MCC 并接受随访的患者。排除无随访数据的患者。数据分析于 2022 年 3 月 12 日至 11 月 30 日进行。
采用 Cox 比例风险回归分析确定人口统计学变量(种族和民族、年龄、性别和收入)与临床变量(诊断时的分期、原发部位和诊断年份)与 MCC 特异性生存之间的关联。
在确定的 9557 例 MCC 患者中(≥70 岁 6758 例[70.7%];男性 6008 例[62.9%]),222 例(2.3%)为亚裔或太平洋岛民,146 例(1.5%)为黑人,541 例(5.7%)为西班牙裔,8590 例(89.9%)为白人。与白人患者相比,西班牙裔患者的 MCC 特异性生存率更高(风险比,0.82;95%CI,0.67-0.99;P=0.04)。黑人患者的 MCC 特异性生存率最低,但与白人患者相比无统计学差异(风险比,1.19;95%CI,0.86-1.60;P=0.28)。与白人患者相比,西班牙裔和黑人患者原发部位更倾向于头颈部(541 例中的 183 例[33.8%]和 146 例中的 45 例[30.8%],而 8590 例中的 3736 例[43.5%];P<0.001 和 P=0.002)。黑人患者就诊时更常处于晚期疾病(146 例中的 59 例[40.4%]和 8590 例中的 2510 例[29.2%];P=0.004)。
在这项队列研究中,不同种族和族裔群体在观察到的 MCC 结局和疾病特征方面存在差异。需要进一步研究发现,与白人患者相比,西班牙裔 MCC 患者的结局有所改善,而黑人患者尽管疾病更晚期,但其结局却没有更差。